BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524661

WELCURE

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

WELCURE DRUGS & PHARMACEUTICAL Share Price Update

As of the latest trading session, WELCURE DRUGS & PHARMACEUTICAL share price is currently at ₹ 6.64, which is up by ₹ 0.30 from its previous closing. Today, the stock has fluctuated between ₹ 6.47 and ₹ 6.64. Over the past year, WELCURE DRUGS & PHARMACEUTICAL has achieved a return of -17.68 %. In the last month alone, the return has been -36.82 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

WELCURE DRUGS & PHARMACEUTICAL fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    74.70

  • P/E Ratio (TTM)

    2.57

  • Beta

    0.57

  • Book Value / share

    9.11

  • Return on equity

    3.81%

  • EPS (TTM)

    2.46

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    23.30

info icon alternate text

WELCURE DRUGS & PHARMACEUTICAL Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 299.91
Operating Expense 268.78
Net Profit 23.30
Net Profit Margin (%) 7.76
Earnings Per Share (EPS) 2.07
EBITDA 31.14
Effective Tax Rate (%) 25.17
Particulars MAR 2025 (Values in Cr)
Revenue 21.21
Operating Expense 20.58
Net Profit 2.54
Net Profit Margin (%) 11.97
Earnings Per Share (EPS) 0.33
EBITDA 2.55
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.88
Operating Expense 0.79
Net Profit 0.04
Net Profit Margin (%) 4.54
Earnings Per Share (EPS) 0.04
EBITDA 0.09
Effective Tax Rate (%) 55.55
Particulars SEP 2024 (Values in Cr)
Revenue 24.55
Operating Expense 22.71
Net Profit 1.84
Net Profit Margin (%) 7.49
Earnings Per Share (EPS) 0.16
EBITDA 1.85
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.34
Net Profit -0.34
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.26
EBITDA -0.34
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 24.55
Operating Expense 23.68
Net Profit 2.17
Net Profit Margin (%) 8.83
Earnings Per Share (EPS) 0.36
EBITDA 2.78
Effective Tax Rate (%) 21.94
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.27
Net Profit -0.17
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.13
EBITDA -0.13
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 0.14
Net Profit 0.10
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.08
EBITDA 0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.11
Operating Expense 0.08
Net Profit 0.02
Net Profit Margin (%) 18.18
Earnings Per Share (EPS) 0.02
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.08
Net Profit 0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.05
EBITDA 0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2008 (Values in Cr)
Book Value / Share 5.64
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.42
EBITDA Margin -3.61
Particulars MAR 2007 (Values in Cr)
Book Value / Share 7.23
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.41
EBITDA Margin -0.40
Particulars MAR 2006 (Values in Cr)
Book Value / Share 7.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.21
EBITDA Margin -5.76
Particulars MAR 2005 (Values in Cr)
Book Value / Share 9.57
ROE % 3.45
ROCE % 6.33
Total Debt to Total Equity 0.15
EBITDA Margin 4.42
Particulars MAR 2004 (Values in Cr)
Book Value / Share 9.47
ROE % 2.79
ROCE % 5.32
Total Debt to Total Equity 0.24
EBITDA Margin 3.05
Particulars MAR 2025 (Values in Cr)
Book Value / Share 9.12
ROE % 3.81
ROCE % 2.42
Total Debt to Total Equity 1.19
EBITDA Margin 11.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.00
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.13
ROE % 0.62
ROCE % 0.62
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 0.08
ROE % 0.16
ROCE % 0.16
Total Debt to Total Equity 0.00
EBITDA Margin 18.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 0.06
ROE % 0.98
ROCE % 0.98
Total Debt to Total Equity 0.00
EBITDA Margin 46.15
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 266.97
Total Liabilities 266.97
Total Equity 102.51
Share Outstanding 112439100
Price to Book Ratio 1.00
Return on Assets (%) 0.81
Return on Capital (%) 0.96
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 1.37
Total Liabilities 1.37
Total Equity 1.34
Share Outstanding 13512100
Price to Book Ratio 3.76
Return on Assets (%) -12.74
Return on Capital (%) -13.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 1.52
Total Liabilities 1.52
Total Equity 1.51
Share Outstanding 13512100
Price to Book Ratio 3.56
Return on Assets (%) 6.65
Return on Capital (%) 6.71
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 0.09
Total Liabilities 0.09
Total Equity 0.09
Share Outstanding 13512100
Price to Book Ratio 122.13
Return on Assets (%) 24.35
Return on Capital (%) 25.35
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 0.07
Total Liabilities 0.07
Total Equity 0.06
Share Outstanding 13512100
Price to Book Ratio 31.33
Return on Assets (%) 75.52
Return on Capital (%) 79.44
Particulars MAR 2025 (Values in Cr)
Net Income 2.78
Cash from Operations -222.02
Cash from Investing -0.06
Cash from Financing 222.19
Net change in Cash 0.10
Free Cash Flow -222.01
Particulars MAR 2024 (Values in Cr)
Net Income -0.17
Cash from Operations -0.12
Cash from Investing 0.16
Cash from Financing -0.01
Net change in Cash 0.02
Free Cash Flow -0.12
Particulars MAR 2023 (Values in Cr)
Net Income 0.10
Cash from Operations 0.10
Cash from Investing 0.00
Cash from Financing -0.17
Net change in Cash -0.06
Free Cash Flow 0.10
Particulars MAR 2022 (Values in Cr)
Net Income 0.02
Cash from Operations 0.01
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.01
Free Cash Flow 0.01
Particulars MAR 2021 (Values in Cr)
Net Income 0.05
Cash from Operations 0.04
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.04
Free Cash Flow 0.04
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.26 15.21 2.03 285.54 30.00 / 68.00
BLISS GVS PHARMA LTD 154.00 15.25 1.54 1626.39 105.05 / 190.65
CIPLA LTD 1513.75 22.67 3.91 122275.53 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 322.10 9.07 2.61 947.97 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2735.75 48.94 23.75 46345.26 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.26 20.25 5.88 285.54 30.00 / 68.00
AMRUTAJAN HEALTH LTD 714.10 37.86 6.32 2064.51 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9398.00 111.10 30.49 23495.00 6222.35 / 10653.05
BLISS GVS PHARMA LTD 154.00 23.02 1.53 1626.39 105.05 / 190.65

WELCURE DRUGS & PHARMACEUTICAL shareholding pattern

Holding

Others
100.0%
Promoter Holdings
0.0%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Manish Rajput 1.1E7 (9.79%) Public Shareholding
Rahul Ratansingh Sikarwar 1.1E7 (9.79%) Public Shareholding
Avinashbhai Govindbhai Parmar 1.0E7 (8.9%) Public Shareholding
Akshay Nadiya 1.0E7 (8.9%) Public Shareholding
Kuldeep Ranvirsingh Tomar 1.0E7 (8.9%) Public Shareholding
Tatad Nayan Gautambhai 1.0E7 (8.9%) Public Shareholding
Govindsingh Bhavnathsingh Rajbhar 9000000.0 (8.01%) Public Shareholding
Jaydeep Bhosle 9000000.0 (8.01%) Public Shareholding
Mitesh Makvana 9000000.0 (8.01%) Public Shareholding
Ankush Rajkumar Dabhane 6210224.0 (5.53%) Public Shareholding

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

WELCURE DRUGS & PHARMACEUTICAL Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
6.64 4.89 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 6.10
  • 26 Days 7.70
  • 10 Days 6.40
  • 50 Days 8.80
  • 12 Days 6.60
  • 100 Days 9.60
  • 20 Days 7.30
  • 200 Days 9.40
6.23 PIVOT

First Support

6.13

First Resistance

6.43

Second Support

5.93

Second Resistance

6.53

Third Support

5.83

Third Resistance

6.73

RSI

33.28

ADX

55.12

MACD

-1.10

Williams % R

-68.80

Commodity Channel Index (CCI)

-72.12

Date

2025-10-06

Week

3996623.00

Same Day

1843625.00

Month

4539894.00

1 Year

0.58

3 Year

0.56

Over 1 Month

-36.82%

down

Over 1 Year

-17.68%

down

Over 3 Months

-46.21%

down

Over 3 Years

-12.00%

down

Over 6 Months

-23.17%

down

Over 5 Years

25.91%

down

WELCURE DRUGS & PHARMACEUTICAL Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

WELCURE DRUGS & PHARMACEUTICAL Share Price

Incorporated on 4 Jun.'92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc.

WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes.

Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets, capsules and dry syrups, sulpha drugs, vitamins, analgesics, etc. Its subsidiary, AKL, manufactures 6-APA, a key drug intermediate in the manufacture of semi-synthetic penicillin.

The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups.

The new products of the company WELSTAP , X- CLOX , ETHAMBUTOL, RIFA- Z , CETIRIZIN , NORTIN have been well accepted in the market.

The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside, an alternate to sugar, Saccharin and Aspartame.

The Company has added a new liquid oral plant in Bhiwadi, Rajasthan. It has obtained ISO 9002 certification with double accredition from ABS Quality Evaluation Inc Texas and by Registrar of Accredition Board of USA. Welcure has also entered into an agreement with Bihar Drugs and Chemicals Ltd, a government of Bihar undertaking, for manufacturing their products in its factory on loan basis.

During the year 2000-01 the company had launched some products like CEZEN,DIMCIN PLUS,OXIN,SPASWIN etc.The company has entered into technical collaboration agreement with Advanced Medical Care Inc New Jersey USA for setting up of joint venture facilities in the existing plant of the company.

During the year 2001-02, the company had launched products like B-ZEX, DMART PLUS, DRALPIN, DUKESPAS, DUBAMOL, HISTACURE, KUFFWEL, KINGSPAS, LANAX, PETRIMAX, PEEROSCAM, RENACT, SARVO, WELCEE, WELGESIC, WELIC, WELOXY, WELRELEEF, X-DRYL. It changed its marketing policy from 'Sales through Wholesale Distributors' to ' Sales at Doorstep' by reaching every corner of the country and by putting dual force on Sales-through sales personnel on one hand and through stockists and distributors on the other hand.

The Company is carrying on the business of manufacturers, designers, repairers, installers, merchants, importers, exporters, agent for sale and distributors of and dealers in water processing equipment and purifiers, and water softeners of every description. Apart from these, it deals in real estate and engaged in creating exceptional living and working spaces for the new Indian global professionals.

Parent organization Indian Private
NSE symbol [-]
Founded 1996
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

Welcure Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 6.64 as on Oct 07 2025 03:30 PM.

What is the Market Cap of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

The market cap of Welcure Drugs & Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 74.70 as on Oct 07 2025 03:30 PM.

What is the 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 15.89 and ₹ 5.26.

What is 1 year return for Welcure Drugs & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -17.68%.

What is the P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Oct 07 2025 03:30 PM the price-to-earnings (PE) ratio for Welcure Drugs & Pharmaceuticals Ltd share is 2.57.

What is the PB ratio of Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Oct 07 2025 03:30 PM, the price-to-book (PB) ratio for Welcure Drugs & Pharmaceuticals Ltd share is 9.11.

How to Buy Welcure Drugs & Pharmaceuticals Ltd Share?

Answer Field

You can trade in Welcure Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Welcure Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Welcure Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Welcure Drugs & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59